Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CRN on omega-3s

This article was originally published in The Tan Sheet

Executive Summary

A white paper on the "the importance of Omega-3 fatty acids for heart health" notes that following review by FDA and the American Heart Association, "when it comes to omega-3s and heart health, the evidence is strongest for EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid)," the Council for Responsible Nutrition states. The paper was released July 20 by CRN's Omega-3 Working Group. "It is important to educate various audiences on the benefits obtained from the different types of omega-3 fatty acids," according to Ian Newton, executive director of the working group. The paper "helps clarify some of the differences." FDA approved a qualified health claim for EPA and DHA in September (1"The Tan Sheet" Sept. 13, 2004, p. 12)...

You may also be interested in...



Industry Qualifies Enthusiasm For Omega-3 Qualified Health Claim

FDA's qualified health claim linking omega-3 fatty acids to coronary heart disease too narrowly interprets the beneficial relationship, dietary supplement industry stakeholders contend

EU’s SCCS Finds Endocrine-Disrupting Evidence Inconclusive In UV Filter Reassessments

While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.

US FDA Urges COVID-19 Transmission Risk Mitigation In Cell And Gene Therapy Manufacturing

The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.

Topics

UsernamePublicRestriction

Register

LL043624

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel